Connect with us

CWEB Business News

Medtronic Review Post Q1 Results

RBC Capital analysts updated their model and lowered their price target to $110 from $122 on Medtronic (NYSE:MDT) following the company’s recently announced Q1 results and 2023 guidance.
The company’s Q1 EPS came in at $1.13, better than the Street estimate of $1.12. Revenue was $7.4 billion, compared to the Street estimate of $7.22 billion. For the full 2023-year, the company expects EPS to be in the range of $5.53-$5.65, compared to the Street estimate of $5.56.
The analysts lowered their 2023 and 2024 revenue estimates down to $31.59 million (from $31.97 million) and to $33.13 million (from $33.77 million).

Follow us on Google news for more updates and News

Full Disclaimer

More in CWEB Business News



Get the most important news and analyses for Free.

Thank you for subscribing.

Something went wrong.